My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Sep 14,2016

Net profit of Future Enterprises rose 615.37% to Rs 315.48 crore in the quarter ended June 2016 as against Rs 44.10 crore during the previous quarter ended June 2015. Sales declined 67.64% to Rs 921.19 crore in the quarter ended June 2016 as against Rs 2846.84 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales921.192846.84-68
OPM %24.969.91-
PBDT295.07184.1360
PBT142.3249.92185
NP315.4844.10615

Powered by Capital Market - Live News

Ador Multi Products reports consolidated net loss of Rs 0.29 crore in the March 2017 quarter
May 10,2017

Net loss of Ador Multi Products reported to Rs 0.29 crore in the quarter ended March 2017. There were no net profit/loss reported during the previous quarter ended March 2016. Sales rose 20.13% to Rs 1.91 crore in the quarter ended March 2017 as against Rs 1.59 crore during the previous quarter ended March 2016.

For the full year,net profit reported to Rs 0.24 crore in the year ended March 2017 as against net loss of Rs 0.88 crore during the previous year ended March 2016. Sales rose 15.91% to Rs 6.63 crore in the year ended March 2017 as against Rs 5.72 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales1.911.59 20 6.635.72 16 OPM %-25.13-22.64 --20.51-17.31 - PBDT-0.48-0.40 -20 0.59-1.14 LP PBT-0.50-0.44 -14 0.45-1.33 LP NP-0.290 0 0.24-0.88 LP

Powered by Capital Market - Live News

NELCO consolidated net profit declines 62.16% in the March 2017 quarter
May 10,2017

Net profit of NELCO declined 62.16% to Rs 0.98 crore in the quarter ended March 2017 as against Rs 2.59 crore during the previous quarter ended March 2016. Sales rose 6.75% to Rs 36.99 crore in the quarter ended March 2017 as against Rs 34.65 crore during the previous quarter ended March 2016.

For the full year,net profit rose 184.16% to Rs 6.28 crore in the year ended March 2017 as against Rs 2.21 crore during the previous year ended March 2016. Sales declined 28.14% to Rs 143.67 crore in the year ended March 2017 as against Rs 199.94 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales36.9934.65 7 143.67199.94 -28 OPM %9.8414.34 -12.6210.87 - PBDT3.674.33 -15 14.9513.32 12 PBT1.572.59 -39 6.932.21 214 NP0.982.59 -62 6.282.21 184

Powered by Capital Market - Live News

Blue Star consolidated net profit rises 147.63% in the March 2017 quarter
May 10,2017

Net profit of Blue Star rose 147.63% to Rs 37.17 crore in the quarter ended March 2017 as against Rs 15.01 crore during the previous quarter ended March 2016. Sales rose 18.56% to Rs 1371.79 crore in the quarter ended March 2017 as against Rs 1157.05 crore during the previous quarter ended March 2016.

For the full year,net profit rose 17.44% to Rs 123.05 crore in the year ended March 2017 as against Rs 104.78 crore during the previous year ended March 2016. Sales rose 15.53% to Rs 4387.73 crore in the year ended March 2017 as against Rs 3797.96 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales1371.791157.05 19 4387.733797.96 16 OPM %5.245.20 -5.075.66 - PBDT67.9660.02 13 219.21201.45 9 PBT51.3842.37 21 158.63144.36 10 NP37.1715.01 148 123.05104.78 17

Powered by Capital Market - Live News

Marksans Pharma leads gainers on BSEs A group
May 10,2017

Marksans Pharma rose 13.81% at Rs 54.80. The stock topped the gainers in A group. On the BSE, 32.21 lakh shares were traded on the counter so far as against the average daily volumes of 4.74 lakh shares in the past two weeks.

Gujarat Mineral Development Corporation (GMDC) rose 7.33% at Rs 134.65. The stock was the second biggest gainer in A group. On the BSE, 10.84 lakh shares were traded on the counter so far as against the average daily volumes of 46,000 shares in the past two weeks.

Escorts rose 7.04% at Rs 642. The stock was the third biggest gainer in A group. On the BSE, 9.69 lakh shares were traded on the counter so far as against the average daily volumes of 2.19 lakh shares in the past two weeks.

CG Power and Industrial Solutions rose 5.33% at Rs 87.95. The stock was the fourth biggest gainer in A group. On the BSE, 12.38 lakh shares were traded on the counter so far as against the average daily volumes of 3.29 lakh shares in the past two weeks.

Bharti Airtel rose 4.80% at Rs 362.10. The stock was the fifth biggest gainer in A group. On the BSE, 7.57 lakh shares were traded on the counter so far as against the average daily volumes of 1.16 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Bitter pill for AstraZeneca Pharma after reverse turnaround in Q4
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 263.29 points, or 0.88%, to 30,196.54. The S&P BSE Small-Cap index was up 130.87 points, or 0.84% to 15,675.50

On the BSE, 7,662 shares were traded on the counter so far as against the average daily volumes of 6,031 shares in the past one quarter. The stock had hit a high of Rs 968 and a low of Rs 945 so far during the day. The stock had hit a 52-week high of Rs 1,151 on 9 May 2016 and a 52-week low of Rs 909 on 1 March 2017.

The stock had outperformed the market over the past one month till 9 May 2017, rising 2.76% compared with 1.21% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, gaining 5.09% as against Sensexs 5.81% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma Indias total income dropped 26.66% to Rs 118.01 crore in Q4 March 2017 over Q4 March 2016.

AstraZeneca Pharma India is engaged in the development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. AstraZeneca Pharmaceuticals AB holds 75% stake in AstraZeneca Pharma India (as per the shareholding pattern as on 31 March 2017).

Powered by Capital Market - Live News

Premco Global consolidated net profit declines 59.24% in the March 2017 quarter
May 10,2017

Net profit of Premco Global declined 59.24% to Rs 1.39 crore in the quarter ended March 2017 as against Rs 3.41 crore during the previous quarter ended March 2016. Sales rose 7.22% to Rs 15.74 crore in the quarter ended March 2017 as against Rs 14.68 crore during the previous quarter ended March 2016.

For the full year,net profit declined 33.99% to Rs 8.33 crore in the year ended March 2017 as against Rs 12.62 crore during the previous year ended March 2016. Sales rose 1.93% to Rs 71.47 crore in the year ended March 2017 as against Rs 70.12 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales15.7414.68 7 71.4770.12 2 OPM %26.8739.37 -23.8728.65 - PBDT3.206.11 -48 16.2721.68 -25 PBT2.435.53 -56 13.3319.47 -32 NP1.393.41 -59 8.3312.62 -34

Powered by Capital Market - Live News

Alembic consolidated net profit rises 21.98% in the March 2017 quarter
May 10,2017

Net profit of Alembic rose 21.98% to Rs 30.24 crore in the quarter ended March 2017 as against Rs 24.79 crore during the previous quarter ended March 2016. Sales rose 18.80% to Rs 32.92 crore in the quarter ended March 2017 as against Rs 27.71 crore during the previous quarter ended March 2016.

For the full year,net profit declined 38.00% to Rs 145.39 crore in the year ended March 2017 as against Rs 234.51 crore during the previous year ended March 2016. Sales rose 7.59% to Rs 144.26 crore in the year ended March 2017 as against Rs 134.08 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales32.9227.71 19 144.26134.08 8 OPM %4.80-5.95 -4.664.56 - PBDT4.580.57 704 37.5334.69 8 PBT3.31-1.82 LP 32.4428.55 14 NP30.2424.79 22 145.39234.51 -38

Powered by Capital Market - Live News

Tata Motors announces Group global wholesale figures
May 10,2017

Tata Motors Group global wholesales in April 2017, including Jaguar LandRover, were at 73,691 nos., lower by 4%, over April 2016.

Global wholesales of all Tata Motors commercial vehicles and Tata Daewoo range in April 2017 were at 18,844 nos., lower by 36%, over April 2016.

Global wholesales of all passenger vehicles in April 2017 were at 54,847 nos., higher by 16%, compared to April 2016.

Global wholesales for Jaguar Land Rover were 41,923 vehicles. Jaguar wholesales for the month were 12,608 vehicles, while Land Roverwholesales for the month were 29,315 vehicles.

Powered by Capital Market - Live News

Board of Rajoo Engineers approves preferential issue of convertible warrants
May 10,2017

Rajoo Engineers announced that the Board of Directors of the Company at its meeting held on 10 May 2017 approved Preferential offer and Issue of up to 35,00,000 (Thirty Five Lakhs) Warrants convertible to Equity Shares of Re. 1/- each to Promoters and Individuals other than Promoters and Promoters Group subject to the approval of the Members of the Company in General Meeting by way of Special Resolution as required to be passed under Section 42 and Section 62 of the Companies Act, 2013 and other necessary regulatory approvals. The Warrants will be issued at a price not lower than the price arrived at as per the Provisions of Chapter VII of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended and on such further terms and conditions specified in the said Regulations.

Powered by Capital Market - Live News

Marksans Pharmas Goa plant gets approved by UK MHRA
May 10,2017

Marksans Pharma announced that the Companys plant in Goa has been approved by UK MHRA. The plant was inspected by UK MHRA from 14 February 2017 to 17 February 2017.

Powered by Capital Market - Live News

Flop show for Shemaroo Entertainment after poor Q4 result
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 228.69 points, or 0.76% to 30,161.94. The S&P BSE Small-Cap index was up 117.11 points, or 0.75% to 15,661.74

On BSE, so far 38,000 shares were traded in the counter, compared with an average volume of 10,174 shares in the past one quarter. The stock hit a high of Rs 390.10 and a low of Rs 349.05 so far during the day. The stock hit a record high of Rs 439.45 on 23 January 2017. The stock hit a 52-week low of Rs 294 on 29 September 2016.

The stock had underperformed the market over the past one month till 9 May 2017, rising 0.1% compared with 1.21% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, falling 4.1% as against Sensexs 5.81% rise.

The small-cap company has an equity capital of Rs 27.18 crore. Face value per share is Rs 10.

Shemaroo Entertainments EBITDA (earnings before interest, taxes, depreciation and amortization) decreased by 4.6% to Rs 32.36 crore in Q4 March 2017 over Q4 March 2016. EBITDA margin stood at 32.6% in Q4 March 2017 as against 33% in Q4 March 2016.

Hiren Gada, Wholetime Director and CFO, Shemaroo Entertainment said that the Q4 March 2017 traditional media business was affected due to ad slowdown post demonetization. The companys focus on digital media business has continued to yield positive results and it continues to strengthen the growth trajectory by adding quality content to library.

Shemaroo Entertainment is an established filmed entertainment Content House in the country, active in Content Ownership, Creation, Aggregation and Distribution with a large content library of over 3,400 titles. Shemaroo is engaged in the distribution of content for satellite channels, physical formats and emerging digital technologies like the Mobile, Internet, Broadband, IPTV and DTH among others.

Powered by Capital Market - Live News

Blue Star chills after strong Q4 outcome
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 252.21 points or 0.84% at 30,185.46. The S&P BSE Mid-Cap index was up 133.72 points or 0.9% at 14,954.85

On BSE, so far 14,000 shares were traded in the counter as against average daily volume of 19,301 shares in the past one quarter. The stock hit a high of Rs 722.60 and a low of Rs 706 so far during the day. The stock had hit a record high of Rs 723.95 on 5 April 2017. The stock had hit a 52-week low of Rs 407.65 on 24 June 2016.

The stock had outperformed the market over the past one month till 9 May 2017, rising 5.47% compared with 1.21% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 29.65% as against Sensexs 5.81% rise.

The mid-cap company has equity capital of Rs 19.11 crore. Face value per share is Rs 2.

Blue Stars consolidated net profit rose 17.44% to Rs 123.05 crore on 15.53% growth in net sales to Rs 4,387.73 crore in the year ended 31 March 2017 (FY 2017) over FY 2016. Blue Star said that consequent to the corporate restructuring implemented in FY 2016, previous years numbers have been restated wherever required under IND AS and also to give effect to the restructuring. Therefore, the FY 2017 performance is not directly comparable with the previous years numbers.

The companys consolidated total operating income rose 22% to Rs 4424.72 crore for FY 2017 over FY 2016 (excluding BSILs operating income of Rs 205.09 crore). Operating Profit (PBIDTA excluding other non operating income) rose 20% Rs 256.99 crore in FY 2017 over FY 2016 (excluding BSILs PBIDTA of Rs 31.16 crores).

Other income (including finance income) rose 45.97% to Rs 34.58 crores in FY 2017 over FY 2016 (excluding BSILs other income of Rs 5.98 crore) mainly on account of higher interest on income tax refunds and net forex gain. There were no exceptional items during FY 2017 as compared to an exceptional expense of Rs 11.89 crore in FY 2016.

Carry forward order book as on 31 March 2017 grew by 21% to Rs 1940 crore in FY 2017 over FY 2016.

In its outlook, Blue Star said that while the electro-mechanical projects business continues to be adversely affected due to the slowdown in commercial construction, government-funded infrastructure projects have been witnessing some growth resulting in some traction in this segment. The unitary products business has been performing impressively driven by the companys strong brand equity and enhanced distribution footprint. Given the early onset of summer and the forecast of a normal monsoon coupled with addition of new product lines such as water purifiers and air purifiers, the prospects of this business look promising. Overall, the company is confident of sustaining its growth momentum in FY 2018 as well.

Blue Star is Indias leading central airconditioning company. The company fulfils the airconditioning needs of a large number of corporate, commercial and residential customers and has also established leadership in the field of commercial refrigeration.

Powered by Capital Market - Live News

Fertiliser shares in demand
May 10,2017

Chambal Fertilisers & Chemicals (up 10.05%), Rashtriya Chemicals and Fertilisers (up 7.83%), Fertilisers & Chemicals Travancore (up 5.41%), National Fertilizers (up 2.63%), Zuari Global (up 2.30%), Coromandel International (up 2.14%), Tata Chemicals (up 2.09%), Gujarat State Fertilizers & Chemicals (up 2.02%) and Deepak Fertilisers & Petrochemicals Corporation (up 0.67%), edged higher.

The S&P BSE Sensex was up 229.94 points, or 0.77% at 30,163.19.

India looks likely to receive above average monsoon rainfall as concern over the El Nino weather condition has eased in the past few weeks, India Meteorological Department (IMD) Director General KJ Ramesh was quoted by the media yesterday, 9 May 2017, raising prospects of higher farm and economic growth.

The IMD on 18 April 2017 forecast this years monsoon rains at 96% of a 50-year average of 89 cm. El Nino is a phenomenon associated with warming of ocean surface temperatures in the eastern and central Pacific that typically occurs every few years.

However, Ramesh reportedly denied the possibility that monsoon would be above normal this year. Anything between 96% and 104% of the long period average (LPA) is considered as normal. Anything under 96% is considered as below normal and 104-110% of the LPA as above normal.

Powered by Capital Market - Live News

Jubilant Life Sciences gains after resuming Gajraula operations
May 10,2017

The announcement was made after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 245.10 points, or 0.82% to 30,178.35.

On the BSE, 55,000 shares were traded in the counter so far, compared with average daily volumes of 99,595 shares in the past one quarter. The stock had hit a high of Rs 797.95 and a low of Rs 774 so far during the day. The stock hit a record high of Rs 879.10 on 12 April 2017. The stock hit a 52-week low of Rs 294.20 on 24 June 2016.

The stock had underperformed the market over the past one month till 9 May 2017, falling 5.32% compared with 1.21% rise in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 9.49% as against Sensexs 5.81% rise.

The large-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.

The National Green Tribunal (NGT) has passed an order allowing the company to restart manufacturing operations in all its units at Gajraula (except the distillery unit) in compliance with the directions issued by the NGT in this regard. The company said it has complied with the directions issued by NGT and has, with effect from yesterday, 9 May 2017, restarted its manufacturing operations in Gajraula (except the distillery unit). The revenue impact of the distillery operations in financial year ended March (FY 2017) is not significant.

The company said it operates its manufacturing facilities in Gajraula with zero liquid discharge. In 2016, the companys manufacturing facilities in Gajraula were awarded the gold category for their sustainability performance and were rated amongst the top 5% global performers as evaluated by EcoVadis during its latest evaluation.

The company assured that all its manufacturing facilities including those at Gajraula comply with all applicable laws.

On 27 April 2017, Jubilant Life Sciences informed that NGT ordered 13 industrial units situated in Gajraula to immediately cease operations after a hearing on Ganga pollution case.

On a consolidated basis, Jubilant Life Sciences net profit fell 2.6% to Rs 119.78 crore on 8.7% rise in net sales to Rs 1438.81 crore in Q3 December 2016 over Q3 December 2015.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions. The pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma, is engaged in manufacture and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile and non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada.

Powered by Capital Market - Live News

Moodys: Outlook for global shipping industry is stable; EBITDA to stay steady
May 10,2017

Moodys Japan K.K. says that the outlook for the global shipping industry is stable, given that -- after excluding M&As and spinoffs -- the aggregate EBITDA of rated shipping companies will remain at similar levels in 2017 as last year.

Unlike 2016, when the industry saw double-digit EBITDA declines, the operating environment has bottomed and earnings will remain stable, although at a low level during 2017. However, a material level of industrywide earnings growth will be beyond our 12-month horizon.

Moodys conclusions are contained in its recently released report on the global shipping sector, Outlook Update: Shipping - Global, Stable Outlook Reflects Easing of Dry Bulk, Containership Excess Capacity; Flat EBITDA.

Moodys further notes that the continued scrapping of Panamax-class vessels driven by the expansion of the Panama Canal and of older ships driven by tightening environmental regulations are likely to continue, partly offsetting global capacity expansion, a credit positive.

Further driving the stable outlook for the global shipping sector are signs of a recovery in the dry bulk and containership segments.

Market conditions are still weak, but are unlikely to worsen from the levels seen for both segments in 2016, and we expect that supply growth will exceed demand growth by less than 2%, or within our parameter for a stable view. Freight rates in these two segments will also gradually increase.

As indicated, Moodys view on the dry bulk segment is stable. Freight rates have improved on the back of a decrease in order books combined with continuous demand from China.

Our view on the containership segment is also stable, as supply growth will continue to outpace demand growth in 2017, causing freight rates to remain low, but higher than last years levels.

Meanwhile, our view on the tanker segment is negative, reflecting high supply and low freight rates. The segment faces very high levels of scheduled deliveries for 2017 and 2018, a credit-negative development because it will keep freight rates low over the coming 12 months.

For the shipping industry generally, we would consider changing the outlook back to negative if we see signs that shipping supply growth will exceed demand growth by more than 2% or that aggregate EBITDA will decline by more than 5% year over year. Downside risks remain high.

Conversely, we would consider a positive outlook if the oversupply of vessels declines materially and aggregate year-over-year EBITDA growth appears likely to exceed 10%.

Powered by Capital Market - Live News